FierceBiotech Radio on pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

This week's episode is sponsored by Catalent.

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.